Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Finished Goods (2021 - 2025)

Organogenesis Holdings (ORGO) has 5 years of Finished Goods data on record, last reported at $14.0 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 16.43% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $14.0 million, up 16.43%, while the annual FY2025 figure was $14.0 million, 16.43% up from the prior year.
  • Finished Goods reached $14.0 million in Q4 2025 per ORGO's latest filing, down from $24.4 million in the prior quarter.
  • Across five years, Finished Goods topped out at $24.4 million in Q3 2025 and bottomed at $10.4 million in Q2 2023.
  • Average Finished Goods over 5 years is $13.9 million, with a median of $12.8 million recorded in 2023.
  • Peak YoY movement for Finished Goods: dropped 23.51% in 2022, then soared 87.48% in 2025.
  • A 5-year view of Finished Goods shows it stood at $15.0 million in 2021, then decreased by 23.51% to $11.5 million in 2022, then grew by 25.93% to $14.5 million in 2023, then decreased by 16.68% to $12.0 million in 2024, then increased by 16.43% to $14.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $14.0 million in Q4 2025, $24.4 million in Q3 2025, and $18.3 million in Q2 2025.